PhD Studentship - Genetic and Therapeutic Determinants of Adverse Drug Reactions in Cardio-Renal DiseasesUniversity

The GW4 BioMed3 Doctoral Landscape Programme is offering up to 18 MRC funded studentships across a range of biomedical disciplines, with a start date of October 2027.

These four-year studentships provide funding for fees and stipend at the rate set by the UKRI, as well as other research training and support costs, and are available to UK and International students.

This project is in competition for place with the projects across the MRC GW4 BioMed3 Doctoral Landscape Award studentships. There are a total of 18 studentships available across the partnership.

Why do people with cardiometabolic diseases experience different health trajectories despite similar treatment? This interdisciplinary PhD project will investigate how genetic variation, prescribing, and patient characteristics influence treatment response, drug safety, and health. Leveraging health data science techniques developed by Exeter AGE Group, you will analyse linked genomic and clinical records data from cohorts of millions of people (including UK Biobank and Our Future Health) to, with embedded training and career development. Focusing on cutting-edge therapies like SGLT2 inhibitors and DOACs, your discoveries could help prevent adverse outcomes like falls and kidney injury, informing precision medicine and NHS clinical guidance.

These studentships are funded through GW4 BioMed3 MRC Doctoral Landscape Programme and consist of UK tuition fees, as well as a Doctoral Stipend matching UK Research Council National Minimum (£21,805 p.a. for 2026/27, updated each year).

Additional research training and support funding of up to £5,000 per annum is also available.

£21,805 per annum - Funding Comment (less than 100 characters) - Stipend matching UK Research Council National Minimum (£21,805 per annum updated each year) plus UK/Home tuition fees